Skip to content
Jubilant Pharmova logo

Jubilant Pharmova

JUBLPHARMA NSE
₹939.55 +0.80 (+0.09%)
P/E
42.49
View as Markdown
MCP
Close 4 Nov 2026 ₹939.55 −221.35 −19.1% 1Y
Start ₹1,160.90

Key Fundamentals

SmallcapPharmaceuticals & BiotechnologyHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
8.99%
Debt to Equity
0.51
EPS (TTM)
₹22.11
Book Value
₹445.26
Market Cap
—
P/E (TTM)
42.49
P/B
2.11
ROE
6.53%
Dividend Yield
0.53%
EBITDA
₹1,326 Cr
52W High
₹1,170.00
52W Low
₹786.05
Day Range
₹933.00 – ₹953.00
Volume
50,216

Peer Comparison

Healthcare › Pharmaceuticals

Jubilant Pharmova peer comparison
Sun Pharma
₹1,773.4038.81₹4,29,049 Cr4.770.90%16.00%20.50%₹61,631 Cr₹10,987 Cr
Divis Laboratories
₹10,037.5091.10₹2,65,269 Cr15.900.30%16.50%22.00%₹11,230 Cr₹2,925 Cr
Torrent Pharmaceuticals
₹4,738.5078.61₹1,77,061 Cr9.810.82%27.40%15.20%₹17,400 Cr₹2,099 Cr
Zydus Life Science
₹1,188.1026.44₹1,25,446 Cr4.370.08%21.20%21.10%₹28,592 Cr₹4,593 Cr
Laurus Labs
₹2,323.80114.81₹1,25,228 Cr20.720.04%18.30%17.80%₹7,270 Cr₹1,090 Cr
Dr Reddys Laboratories
₹1,374.0035.59₹1,14,543 Cr2.960.58%11.20%13.00%₹33,228 Cr₹3,184 Cr
Cipla
₹1,402.0033.59₹1,12,454 Cr3.200.93%11.60%15.50%₹28,324 Cr₹3,356 Cr
Jubilant Pharmova (this company)
₹939.5542.49₹15,094 Cr2.110.53%6.53%8.99%₹8,608 Cr₹351 Cr
Median 8 companies₹1,587.7040.65₹1,25,337 Cr4.570.55%16.25%16.65%₹22,862 Cr₹3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

45 Average

Data confidence 100/100

Category scores

Quality
36
Poor
Returns, margins, earnings quality 22% weight
Valuation
57
Good
Cheap vs sector & own history 24% weight
Growth
49
Average
Sales & profit trajectory 9% weight
Financial Health
15
Poor
Solvency, leverage, coverage 9% weight
Momentum
30
Poor
Trend strength, vol-adjusted 12% weight
Ownership
52
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has been maintaining a healthy dividend payout of 43.9%
  • Company's working capital requirements have reduced from 28.6 days to 13.4 days

Weaknesses

3
  • The company has delivered a poor sales growth of 6.31% over past five years.
  • Company has a low return on equity of 4.91% over last 3 years.
  • Company might be capitalizing the interest cost

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1072
OscillatorsBullish072
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
45.00
Neutral
MACD (12,26,9)
−10.68
Bullish
SMA (50)
966.41
Bearish
SMA (200)
943.48
Bearish

As of

Analyst Rating

Based on 3 analysts
BUY67%

2 of 3 analysts rate Buy, 0 Hold, 1 Sell.

As of

BUY
2
67%
HOLD
0
0%
SELL
1
33%

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y+3.72%
5Y+6.31%
3Y+9.64%
1Y+14.46%
TTM+16.25%

Net profit

Net profit growth by window
10Y+0.28%
5Y−13.79%
3YTurned to profit
1Y−52.39%
TTM−23.03%

Operating cash flow

Operating cash flow growth by window
10Y+1.11%
5Y−7.21%
3Y+22.90%
1Y+14.46%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−6.63 pp
5Y−7.78 pp
3Y+2.82 pp
1Y−1.00 pp
TTM−2.22 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹5,861 Cr
Mar 2018₹7,518 Cr
Mar 2019₹9,111 Cr
Mar 2020₹5,976 Cr
Mar 2021₹6,099 Cr
Mar 2022₹6,130 Cr
Mar 2023₹6,282 Cr
Mar 2024₹6,703 Cr
Mar 2025₹7,234 Cr
Mar 2026₹8,280 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹575 Cr
Mar 2018₹634 Cr
Mar 2019₹577 Cr
Mar 2020₹898 Cr
Mar 2021₹836 Cr
Mar 2022₹413 Cr
Mar 2023−₹65.00 Cr
Mar 2024₹73.00 Cr
Mar 2025₹836 Cr
Mar 2026₹398 Cr

Analyst Forecasts

Forecast For
Sep 26 consensus · EBITDA
₹236 Cr −9.2% vs Jun 26
Reported High Mean Low

AI Analysis — Bull vs Bear

Figures as of 30 Oct 2026
AI opinion · based on fundamentals
Risk high

Jubilant Pharmova Ltd trades at ₹923.8 with a market cap of ₹14,714 crore and a PE of 41.78x as of 2026-10-30. The company shows a sharp divergence between recent sales growth (16% TTM) and profit decline (-20% TTM), while carrying moderate leverage at a debt-to-equity ratio of 0.51.

Bull Case 7
  • TTM revenue growth has accelerated to 16%, well above the 5-year compounded sales growth of 6%, suggesting improving top-line momentum
  • 3-year compounded profit growth stands at 47%, indicating a strong medium-term earnings recovery cycle despite recent TTM weakness
  • Working capital efficiency has improved significantly, with working capital days declining from 28.6 days to 13.4 days, freeing up cash for operations
  • The company maintains a healthy dividend payout ratio of 43.9%, with a current dividend yield of 0.53%, reflecting a shareholder-friendly capital allocation policy
  • The stock trades about 21.9% below its 52-week high of ₹1,183, which may indicate a potential mean-reversion opportunity for those who believe fundamentals are intact
  • 3-year stock CAGR of 32% demonstrates strong medium-term wealth creation for investors over that period
  • Debt-to-equity of 0.51 is moderate and manageable for a pharma company with CDMO and generics operations, and the price-to-book of 2.07x is not stretched relative to healthcare peers
Bear Case 8
  • TTM profit has declined by 20%, a sharp reversal that raises concerns about margin sustainability despite top-line growth of 16%
  • PE of 41.78x on a TTM EPS of ₹22.11 is elevated, especially given the current earnings decline trajectory
  • Return on equity stands at just 5.6% currently and averages only 5% over the last 3 years, well below the 10-year average of 9%, signalling deteriorating capital efficiency
  • ROCE of 6.36% is low, suggesting the company is not generating strong returns on total capital employed including debt
  • 5-year compounded sales growth of just 6% and 5-year compounded profit decline of -13% point to a structurally weak medium-term earnings trajectory
  • The 1-year stock CAGR is -15%, indicating recent underperformance and negative price momentum
  • There are indications the company may be capitalizing interest costs, which could flatter reported profitability and understate the true interest burden on operations
  • 10-year compounded profit growth of only 1% suggests the company has struggled to deliver consistent long-term earnings growth

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

9h ago

TL;DR: Jubilant Pharmova is aggressively building its debt toolkit — tapping the local bond market for the first time with an AA+ rated ₹800 crore issue and seeking broader NCD headroom of up to ₹2,500 crore to fund capex and refinance overseas liabilities. The institutional ownership shift (Quant MF exit absorbed partly by Abakkus) created short-term price pressure but did not signal broad institutional flight. The key forward risk is rising leverage if capex returns take time to materialise, while the positive trend is expanding capacity that the rating agency expects to strengthen the business profile over the medium term.

Headwinds 1
  • Quant MF exits, sells 1.3% stake Oct 12

    Quant Mutual Fund sold 20.81 lakh shares (~1.3% of paid-up equity) at ₹915 per share for roughly ₹190 crore. Shares fell 2.32% to ₹928.80 on the session following the block deal.

Positives 3
  • Abakkus accumulates ₹101 cr stake Oct 12

    Abakkus Asset Managers acquired 11 lakh shares at ₹915 apiece for ₹101 crore, raising its holding to 1.84% from 1.15%. The buy partially absorbed Quant MF's exit block.

  • AA+ rated maiden bond issue Nov 03

    Jubilant Pharmova raised ₹800 crore via its first-ever local bond issue (3-year tenure, ~8.50% coupon), with a ₹400 crore base and equal greenshoe. Bonds are rated AA+ and expected to be subscribed mainly by mutual funds and asset managers.

  • Capex-driven growth spending Oct 23

    The company plans up to ₹1,400 crore in rupee bond issuance for capital expenditure and refinancing overseas subsidiary liabilities, following ₹1,450 crore capex in the prior financial year. Rating agency expects the business profile to strengthen from recently commissioned capacities.

Neutral 3
  • ₹2,500 cr NCD approval sought Oct 21

    Jubilant Pharmova initiated a postal ballot (e-voting Oct 22–Nov 20, 2026) seeking shareholder approval to issue NCDs up to ₹2,500 crore outstanding at any point over one year.

  • Board approves ₹800 cr NCD issue Oct 12

    The board approved issuance of up to 80,000 NCDs of ₹1 lakh face value each aggregating ₹800 crore, with tenure up to 5 years, to be listed on BSE.

  • Board meeting for NCD fundraise Oct 07

    Jubilant Pharmova announced a board meeting on October 12, 2026 to consider raising funds through NCDs and other securities.

Quarterly Results

₹ Cr
JUBLPHARMA quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
1,587
1,680
1,677
1,759
1,732
1,752
1,822
1,929
1,901
1,966
2,122
2,290
2,229
Expenses
1,419
1,438
1,459
1,487
1,480
1,463
1,535
1,584
1,611
1,625
1,833
1,951
1,981
Operating Profit
168
242
218
271
252
289
287
345
290
341
289
339
248
OPM %
11%
14%
13%
15%
15%
17%
16%
18%
15%
17%
14%
15%
11%
Other Income
9
19
49
−151
410
8
−10
9
12
4
−19
10
20
Interest
62
66
71
73
71
61
56
53
49
50
56
56
54
Depreciation
90
97
95
101
91
91
91
95
98
105
121
117
127
PBT
26.6
98
101
−54
500
144
131
206
154
190
93
176
86
Tax %
76%
37%
34%
15%
4%
29%
23%
27%
34%
37%
40%
32%
35%
Net Profit
6
62
66
−62
482
102
101
151
102
120
56
119
56
EPS (₹)
0.4
3.92
4.19
−3.68
30.26
6.45
6.33
9.64
6.46
7.55
3.51
7.5
3.55

Profit & Loss

₹ Cr
JUBLPHARMA profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
5,751
5,749
5,861
7,518
9,111
5,976
6,099
6,130
6,282
6,703
7,234
8,280
8,608
Expenses
5,141
4,493
4,510
5,995
7,367
4,428
4,695
4,980
5,503
5,802
6,061
7,020
7,390
Operating Profit
610
1,256
1,352
1,522
1,744
1,548
1,403
1,150
779
901
1,173
1,260
1,218
OPM %
11%
22%
23%
20%
19%
26%
23%
19%
12%
13%
16%
15%
14%
Other Income
86
4
19
36
−249
225
263
8
−9
−76
416
7
15
Interest
368
371
341
284
220
200
184
145
188
272
240
212
217
Depreciation
288
347
291
415
371
340
349
382
554
382
369
440
470
PBT
40
542
738
859
904
1,233
1,133
630
28
170
981
614
546
Tax %
200%
29%
22%
26%
36%
27%
26%
34%
333%
57%
15%
35%
—
Net Profit
−40
387
575
634
577
898
836
413
−65
73
836
398
351
EPS (₹)
−3.63
24.6
36.14
40.35
36.06
56.39
52.47
25.98
−3.83
4.84
52.69
25.02
22.11
Div. Payout %
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
12%
8%
7%
12%
9%
10%
19%
Not meaningful for this period: the ratio divides by a base close to zero, so it is left blank rather than shown as a very large number.
102%
9%
20%
—

Balance Sheet

₹ Cr
JUBLPHARMA balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
16
16
16
16
16
16
16
16
16
Reserves
2,438
2,951
3,420
4,071
4,793
5,588
4,726
5,303
5,383
5,418
6,239
7,077
Borrowings
4,793
4,493
4,045
3,469
4,840
4,808
2,830
3,192
3,677
3,664
2,731
3,615
Other Liabilities
1,372
1,280
1,417
1,902
1,670
1,898
1,192
1,319
1,853
2,240
3,598
4,564
Total Liabilities
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,272
Fixed Assets
4,911
5,104
5,107
5,401
5,648
6,340
4,609
4,871
5,183
5,091
5,176
6,966
CWIP
597
611
684
671
901
768
897
1,090
1,562
2,103
3,630
4,040
Investments
40
85
103
124
115
69
241
239
256
42
44
61
Other Assets
3,071
2,939
3,006
3,262
4,654
5,133
3,017
3,631
3,928
4,101
3,735
4,205
Total Assets
8,619
8,740
8,899
9,457
11,319
12,310
8,763
9,830
10,929
11,338
12,584
15,272

Cash Flow

₹ Cr
JUBLPHARMA cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
783
1,099
1,268
1,303
1,122
1,543
1,784
838
661
971
1,072
1,227
Investing
−362
−309
−465
−614
−1,018
−267
−727
−323
−474
−596
512
−1,143
Financing
−503
−843
−686
−901
657
−1,050
−1,709
−33
−157
−432
−1,453
95
Net Cash Flow
−82
−52
117
−212
761
225
−652
482
30
−58
132
179
Free Cash Flow
434
760
806
819
473
975
1,270
241
−135
83
−38
−120
CFO/OP
141
91
104
103
84
116
155
90
111
131
112
114

Ratios

JUBLPHARMA financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
52
60
63
55
51
79
49
55
56
50
45
47
Inventory Days
169
207
223
177
147
463
268
308
268
220
178
170
Days Payable
99
106
137
145
106
273
124
139
160
146
158
170
Cash Conversion Cycle
122
162
149
87
92
268
194
224
165
124
65
47
Working Capital Days
12
4
50
45
45
62
74
56
57
56
16
13
ROCE %
6%
13%
15%
15%
16%
15%
12%
10%
3%
7%
10%
9%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Jubilant Pharmova insights

70 extracted metrics across FY11–FY27.

Shareholding Pattern

As of Sep 2026

  • Promoters 47.68%
  • Public 23.38%
  • FIIs 15.38%
  • DIIs 13.02%

6.51% of promoter holding pledged as of Sep 2026

Change vs previous quarter

Not shown for some quarters: Others. Not available separately for this quarter: the shareholding filing gives Public and Others as one figure, shown under Public, so Others is left blank rather than estimated.

Documents

Frequently Asked Questions about Jubilant Pharmova

What does Jubilant Pharmova Ltd do?
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.
Where is Jubilant Pharmova Ltd (JUBLPHARMA) listed?
Jubilant Pharmova Ltd trades as JUBLPHARMA on the NSE and under code 530019 on the BSE.
Which sector does Jubilant Pharmova Ltd belong to?
Jubilant Pharmova Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd trades at a PE ratio of 42.49 as of 4 Nov 2026, on earnings per share of ₹22.11, against a book value of ₹445.26 per share.
What is the 52-week high and low of Jubilant Pharmova Ltd?
Over the last 52 weeks Jubilant Pharmova Ltd has traded between ₹786.05 and ₹1,170 as of 4 Nov 2026.
Does Jubilant Pharmova Ltd pay dividends?
Jubilant Pharmova Ltd has a dividend yield of 0.53%.
What is the Return on Equity (ROE) of Jubilant Pharmova Ltd?
Jubilant Pharmova Ltd reported a return on equity of 6.53%. Its debt-to-equity ratio is 0.51.

Company Information

Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.

Website jubl.com
CEO Mr. Priyavrat Bhartia MBA
Employees 5,547
Listed 16 Jun 2003
Face Value ₹1

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/JUBLPHARMA.md for Jubilant Pharmova Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month